S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Biden's Plan to Confiscate Your Cash? (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Biden's Plan to Confiscate Your Cash? (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Biden's Plan to Confiscate Your Cash? (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Biden's Plan to Confiscate Your Cash? (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Biden's Plan to Confiscate Your Cash? (Ad)
NASDAQ:MNPR

Monopar Therapeutics - MNPR Stock Forecast, Price & News

$1.79
-0.01 (-0.56%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.71
$1.80
50-Day Range
$1.79
$2.39
52-Week Range
$1.70
$6.98
Volume
4,826 shs
Average Volume
9,595 shs
Market Capitalization
$22.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Monopar Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
235.3% Upside
$6.00 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Monopar Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

858th out of 1,122 stocks

Pharmaceutical Preparations Industry

431st out of 551 stocks

MNPR stock logo

About Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Monopar Therapeutics Stock Performance

MNPR traded down $0.06 during trading on Wednesday, reaching $1.74. 12 shares of the company were exchanged, compared to its average volume of 8,572. The company's 50-day moving average is $2.16 and its two-hundred day moving average is $2.44. Monopar Therapeutics has a 12-month low of $1.70 and a 12-month high of $6.98.

Analyst Upgrades and Downgrades

Separately, HC Wainwright cut their price target on Monopar Therapeutics from $9.00 to $6.00 and set a "buy" rating for the company in a research note on Tuesday.

Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MNPR Stock News Headlines

Monopar Therapeutics (NASDAQ:MNPR) Shares Up 0.5%
Recap: Monopar Therapeutics Q4 Earnings
Monopar Announces Clinical and Preclinical Program Updates
Monopar Therapeutics Inc. Common Stock (MNPR)
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe
Soft Tissue Cancer
See More Headlines
Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MNPR Company Calendar

Last Earnings
11/12/2021
Today
8/18/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNPR
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+235.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-9,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.14 per share

Miscellaneous

Free Float
7,483,000
Market Cap
$22.78 million
Optionable
Not Optionable
Beta
0.47

Key Executives

  • Dr. Chandler D. Robinson M.B.A. (Age 38)
    M.D., M.Sc., MBA, MSc, Co-Founder, CEO, Pres & Director
    Comp: $659.6k
  • Ms. Kim R. Tsuchimoto CPA (Age 59)
    CFO, Sec. & Treasurer
    Comp: $327.8k
  • Mr. Andrew J. Cittadine M.B.A. (Age 50)
    Chief Operating Officer
  • Dr. Patrice P. Rioux M.D. (Age 71)
    Ph.D., Acting Chief Medical Officer













MNPR Stock - Frequently Asked Questions

Should I buy or sell Monopar Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNPR shares.
View MNPR analyst ratings
or view top-rated stocks.

What is Monopar Therapeutics' stock price forecast for 2022?

2 analysts have issued 1 year target prices for Monopar Therapeutics' shares. Their MNPR share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 235.3% from the stock's current price.
View analysts price targets for MNPR
or view top-rated stocks among Wall Street analysts.

How have MNPR shares performed in 2022?

Monopar Therapeutics' stock was trading at $3.21 at the beginning of the year. Since then, MNPR stock has decreased by 44.2% and is now trading at $1.7897.
View the best growth stocks for 2022 here
.

When is Monopar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our MNPR earnings forecast
.

How were Monopar Therapeutics' earnings last quarter?

Monopar Therapeutics Inc. (NASDAQ:MNPR) released its earnings results on Friday, November, 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.02.

What other stocks do shareholders of Monopar Therapeutics own?
When did Monopar Therapeutics IPO?

(MNPR) raised $9 million in an IPO on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading acted as the underwriter for the IPO and Arcadia Securities was co-manager.

What is Monopar Therapeutics' stock symbol?

Monopar Therapeutics trades on the NASDAQ under the ticker symbol "MNPR."

Who are Monopar Therapeutics' major shareholders?

Monopar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include UBS Group AG (0.16%).
View institutional ownership trends
.

How do I buy shares of Monopar Therapeutics?

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Monopar Therapeutics' stock price today?

One share of MNPR stock can currently be purchased for approximately $1.79.

How much money does Monopar Therapeutics make?

Monopar Therapeutics (NASDAQ:MNPR) has a market capitalization of $22.78 million. The company earns $-9,100,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How can I contact Monopar Therapeutics?

Monopar Therapeutics' mailing address is 1000 SKOKIE BLVD SUITE 350, WILMETTE IL, 60091. The official website for the company is www.monopartx.com. The company can be reached via phone at 847-388-0349 or via email at info@monopartx.com.

This page (NASDAQ:MNPR) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.